Related Experiment Videos
Citalopram for treatment-resistant obsessive-compulsive disorder
S Pallanti1, L Quercioli, R S Paiva
1Istituto di Neuroscienze and University of Florence Medical School, Florence, Italy.
Summary
Adding clomipramine to citalopram significantly improved treatment-resistant obsessive-compulsive disorder (OCD) outcomes. This combination therapy showed greater efficacy than citalopram alone in reducing symptom severity.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Psychology
Background:
- Obsessive-compulsive disorder (OCD) is a debilitating mental health condition.
- Treatment-resistant OCD poses significant challenges, often requiring novel therapeutic strategies.
- Existing treatments like clomipramine and fluoxetine may not be effective for all patients.
Purpose of the Study:
- To compare the efficacy of citalopram monotherapy versus a combination of citalopram and clomipramine in patients with treatment-resistant OCD.
- To evaluate the impact of combined citalopram and clomipramine on symptom severity as measured by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS).
Main Methods:
- A 90-day, randomized, open-label trial involving 16 adult outpatients with moderate to severe OCD.
- Participants had failed prior adequate trials of clomipramine and fluoxetine.
- Patients were assigned to receive either citalopram alone or citalopram combined with clomipramine.
Main Results:
- The group receiving citalopram plus clomipramine (n=9) showed a significantly greater percentage decrease in mean Y-BOCS scores by day 90 compared to the citalopram alone group (n=7).
- All patients (100%) in the combination group achieved at least a 35% decrease in Y-BOCS scores.
- In contrast, only one patient (14%) in the citalopram alone group achieved a >35% decrease, and two (29%) achieved a >25% decrease.
Conclusions:
- Combining citalopram with clomipramine appears more effective than citalopram monotherapy for treatment-resistant OCD.
- The observed improvement is unlikely due to altered clomipramine metabolism, as citalopram does not significantly affect it.
- Further double-blind controlled trials are warranted to confirm the efficacy of citalopram in OCD and the combination therapy for treatment-resistant cases.